Share the post "BIOGEN PHARMACHEM INDUSTRIES announced Financial Results Q1 2024-25"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Profit over the Year and quarter: Challenges in sustaining profitability for BIOGEN PHARMACHEM INDUSTRIES LIMITED. Profit dropped by -138.82 % Year to Year, BIOGEN PHARMACHEM INDUSTRIES LIMITED’s profitability dropped by -121.32 % Quarter to Quarter.
- EPS over the Year and quarter:
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 0.753 Cr | Rs. 0 Cr | Rs. -0.091 Cr | 0 % | -112.08 % |
Expenses | Rs. 0.35 Cr | Rs. 0.04 Cr | Rs. 0.07 Cr | + 75 % | -80 % |
Operating Profit | Rs. 0.4 Cr | Rs. -0.04 Cr | Rs. -0.16 Cr | -300 % | -140 % |
OPM % | 53.12 % | 0 % | 175.82 % | + 175.82 % | + 122.7 % |
Other Income | Rs. 0 Cr | Rs. 0.779 Cr | Rs. 0 Cr | 0 % | 0 % |
Interest | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
Depreciation | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
Profit before tax | Rs. 0.4 Cr | Rs. 0.74 Cr | Rs. -0.16 Cr | -121.62 % | -140 % |
Tax % | 0 % | 0 % | -0 % | 0 % | 0 % |
Net Profit | Rs. 0.41 Cr | Rs. 0.74 Cr | Rs. -0.16 Cr | -121.62 % | -139.02 % |
EPS in Rs | Rs. 0.01 | Rs. 0.01 | Rs. 0 | 0 % | 0 % |
Today, we’re looking at BIOGEN PHARMACHEM INDUSTRIES LIMITED’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -112.08 %. Expenses ticked up slightly by 75 % quarter-on-quarter, aligning with the annual decline of -80 %. Operating profit, while down -140 % compared to last year, faced a quarter-on-quarter dip of -300 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 122.7 %, but an expansion of 175.82 % sequentially. Profit before tax declined annually by -140 % but saw a reduction from the preceding quarter by -121.62 %.
Net profit fell by -139.02 % year-on-year but witnessed a -121.62 % contraction from the last quarter. In summary, BIOGEN PHARMACHEM INDUSTRIES LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 0.753 Cr | Rs. 0 Cr | Rs. -0.091 Cr | 0 % | -112.08 % |
Expenses | Rs. 0.35 Cr | Rs. 0.04 Cr | Rs. 0.07 Cr | + 75 % | -80 % |
Operating Profit | Rs. 0.4 Cr | Rs. -0.04 Cr | Rs. -0.16 Cr | -300 % | -140 % |
Net Profit | Rs. 0.41 Cr | Rs. 0.74 Cr | Rs. -0.16 Cr | -121.62 % | -139.02 % |
EPS in Rs | Rs. 0.01 | Rs. 0.01 | Rs. 0 | 0 % | 0 % |
In reviewing BIOGEN PHARMACHEM INDUSTRIES LIMITED’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -112.08 % year-on-year, Expenses decreased by -80 % compared to the previous year, with a 75 % increase quarter-on-quarter. Operating Profit dropped by -140 % annually, and saw a -300 % decrease from the last quarter.
Net Profit showed yearly decrease of -139.02 %, and experienced a -121.62 % decrease from the previous quarter. In essence, while BIOGEN PHARMACHEM INDUSTRIES LIMITED faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
[my_shortcode1 values=”BIOGEN PHARMACHEM INDUSTRIES “]